<DOC>
	<DOCNO>NCT01971554</DOCNO>
	<brief_summary>This study safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) MK-8666 participant type 2 diabetes mellitus ( T2DM ) . Participants enrol trial would either treatment-naive washed oral anti-hyperglycemic agent . MK-8666 plan administer orally 2 week . The primary hypothesis study 14 day daily treatment MK-8666 , dose safe well tolerate , placebo-corrected fasting plasma glucose reduction baseline ≥34 mg/dL .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamics , Pharmacokinetics MK-8666 Participants With Type 2 Diabetes Mellitus ( MK-8666-003 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>If female , must either postmenopausal surgically sterile A Body Mass Index ( BMI ) ≥18 kg/m^2 ≤40 kg/m^2 , inclusive . A diagnosis T2DM Drug naïve treat 2 oral antihyperglycemic agent ( thiazolidenediones exclude ) Judged good health except T2DM Willing follow standard weight maintain diet throughout study A nonsmoker use nicotine nicotinecontaining product least 3 month A history clinically significant endocrine ( except T2DM ) , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases A history myositis complaint include diffuse myalgia , muscle tenderness , weakness . A history cancer ( malignancy ) except adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix Has clinically unstable diabetic retinopathy , neuropathy , and/or clinical evidence gastroparesis ( frequent nausea , bloat vomiting , severe gastroesophageal reflux , early satiety ) A history type 1 diabetes mellitus and/or history ketoacidosis Taking medication comorbid condition permit study A history significant multiple and/or severe allergy Positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus Had major surgery , donate lose 1 unit blood within 4 week prior study participation Participated another investigational trial within 4 week prior study participation Consumes excessive amount alcoholic caffeinecontaining beverage A regular user illicit drug history drug alcohol abuse within past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>